Posts

Trying to limit calories? Skip the dip, researchers advise

UNIVERSITY PARK, Pa. — Snacks provide, on average, about one-fourth of most peop...

States consider new science-backed solution to save tim...

WEST LAFAYETTE, Ind. — A Purdue University invention that may shorten constructi...

St. Jude gene panel for pediatric cancers increases acc...

Scientists at St. Jude Children’s Research Hospital have created a panel that is...

Drug developed for pancreatic cancer shows promise agai...

A drug that was developed to treat pancreatic cancer has now been shown to incre...

Texas A&M professor named to Committee on Rural Health ...

Dr. Alva O. Ferdinand, head of the Department of Health Policy and Management at...

First full 2-D spectral image of aurora borealis from a...

Auroras are natural luminous phenomena caused by the interaction of electrons fa...

Healthy AI: Sustainable artificial intelligence for hea...

Similar to other sectors around the world, the light speed development of artifi...

Combined effects of plastic pollution and seawater floo...

Two of the planet’s more pressing environmental stressors have the potential to ...

Alpha Cognition’s ALPHA-1062 Becomes the Second Oral FD...

The FDA approved Vancouver-based Alpha Cognition’s ALPHA-1062, also known as Zun...

Novo faces growth challenges despite GLP-1 receptor ago...

The industry is seeking to scale up and satisfy demand for diabetes and obesity ...

Bayer in ecommerce: theme innovation strategy

How many patents did Bayer submit related to ecommerce last quarter, and how man...

Bayer in batteries: theme innovation strategy

How many patents did Bayer submit related to batteries last quarter, and how man...

Amgen in mobile: theme innovation strategy

How many patents did Amgen submit related to mobile last quarter, and how many w...

Amgen in internet of things: theme innovation strategy

How many patents did Amgen submit related to internet of things last quarter, an...

Magazine: Left in limbo: when pharma halts rare disease...

Gene therapy research is expensive. Biotechs invest millions of dollars in early...

FibroGen axes 75% of staff after lead cancer therapy fa...

FibroGen’s pamrevlumab failed to prove its efficacy in two Phase III trials prom...